Advertisement

Clinical and Translational Oncology

, Volume 21, Issue 2, pp 232–238 | Cite as

Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification

  • J. Wei
  • T. Yao
  • Y. Wang
  • L. Li
  • C. Pan
  • N. ZhangEmail author
Research Article
  • 77 Downloads

Abstract

Aim

To study the prognostic factors of gastric cancer (GC) patients who were classified with stage III disease according to the newest TNM classification.

Methods

This study retrospectively enrolled 279 patients who underwent radical gastrectomy from January 2012 to December 2014 at our hospital and who were diagnosed with stage III GC according to the new 8th edition of the TNM classification. The patient data that were collected included age, sex, pathological parameters, survival, lymph node ratio, neo-adjuvant chemotherapy with oxaliplatin and S-1, and operation type. The characteristics, survival, and prognostic factors of the patients were analyzed by univariate and multivariate analyses.

Results

The median OS of the patients after curative surgery was 19 months, and the 3-year survival rate (3-YSR) was 25.3%. A univariate analysis showed that tumor location (P = 0.01), neo-adjuvant chemotherapy (P = 0.005), pathological T stage (P = 0.002), pathological N stage (P < 0.001), lymph node ratio (LNR) (P < 0.001), and operation type (P = 0.032) were significantly associated with overall survival. A multivariate analysis revealed that neo-adjuvant chemotherapy (P = 0.009), pathological T stage (P = 0.012), and LNR (P < 0.001) were independent prognostic factors.

Conclusions

Neo-adjuvant chemotherapy, pathological T stage, and LNR were independent prognostic factors for the overall survival of patients with stage III GC. The neo-adjuvant chemotherapy with oxaliplatin and S-1 can be used for the patients to improve their survival.

Keywords

Gastric cancer Prognosis Multivariate analysis Survival rate Independent prognostic factor 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

Informed consent

Informed consent was provided to all participants.

Ethical approval

This study was reviewed and approved by the Institutional Review Board of the First Hospital Affiliated to Bengbu Medical College, ID#20171015.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2012;65:87–108.CrossRefGoogle Scholar
  2. 2.
    Bu Z, Ji J. A current view of gastric cancer in China. Transl Gastrointest Cancer. 2013;2:1–4.Google Scholar
  3. 3.
    Zeng W, Hu WQ, Wang LW, Yan SG, Li JD, Zhao HL, et al. Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surg. 2014;14:29.CrossRefGoogle Scholar
  4. 4.
    Zhang XF, Huang CM, Lu HS, Wu XY, Wang C, Guang GX, et al. Surgical treatment and prognosis of gastric cancer in 2613 patients. World J Gastroenterol. 2004;10:3405–8.CrossRefGoogle Scholar
  5. 5.
    Mi Sasako, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. Arai K. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.CrossRefGoogle Scholar
  6. 6.
    Mrena J, Mattila A, Bohm J, Jantunen I, Kellokumpu I. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World J Gastroenterol. 2015;21:13294–301.CrossRefGoogle Scholar
  7. 7.
    Chiu CF, Yang HR, Yang MD, Jeng LB, Sargeant AM, Yeh SP, et al. The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation. Springerplus. 2016;5:728.CrossRefGoogle Scholar
  8. 8.
    Peng J, Wei Y, Zhou F, Dai J, Zhong Y, Xie C, et al. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. Cancer Med. 2016;5:2773–80.CrossRefGoogle Scholar
  9. 9.
    Sun Z, Wang Z, Zhu Z, Xu Y, Xu Y, Huang B, et al. Evaluation of the seventh edition of American Joint Committee on Cancer TNM staging system for gastric cancer: results from a Chinese monoinstitutional study. Ann Surg Oncol. 2012;19:1918–27.CrossRefGoogle Scholar
  10. 10.
    Amin MB. AJCC cancer staging manual. 8th ed. New York: Springer-Verlag; 2016. p. 117–27.Google Scholar
  11. 11.
    Choi MG, Sung CO, Noh JH, Kim KM, Sohn TS, Kim S, et al. Mucinous gastric cancer presents with more advanced tumor stage and weaker beta-catenin expression than non-mucinous cancer. Ann Surg Oncol. 2010;17:3053–8.CrossRefGoogle Scholar
  12. 12.
    Hass HG, Smith U, Jager C, Schaffer M, Wellhauber U, Hehr T, et al. Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren’s): single-center experience of 160 cases. Onkologie. 2011;34:682–6.CrossRefGoogle Scholar
  13. 13.
    Lee JH, Nam BH, Ryu KW, Ryu SY, Park YK, Kim S, et al. Comparison of outcomes after laparoscopy-assisted and open total gastrectomy for early gastric cancer. Br J Surg. 2015;102:1500–5.CrossRefGoogle Scholar
  14. 14.
    Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014;32:627–33.CrossRefGoogle Scholar
  15. 15.
    Li MZ, Deng L, Wang JJ, Xiao LB, Wu WH, Yang SB, et al. Surgical outcomes and prognostic factors of T4 gastric cancer patients without distant metastasis. PLoS One. 2014;9:e107061.CrossRefGoogle Scholar
  16. 16.
    Ke B, Song XN, Liu N, Zhang RP, Wang CL, Liang H. Prognostic value of the lymph node ratio in stage III gastric cancer patients undergoing radical resection. PLoS One. 2014;9:e96455.CrossRefGoogle Scholar
  17. 17.
    Sasaki K, Onodera S, Otsuka K, Satomura H, Kurayama E, Kubo T, et al. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Med Oncol. 2017;34(8):139.CrossRefGoogle Scholar
  18. 18.
    Fernandez E, Cacheux W, Frossard JL, Koessler T, Abou M, Moniez M. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma. Dig Liver Dis. 2017;49(5):552–6.CrossRefGoogle Scholar
  19. 19.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Thompson, M. Chir. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefGoogle Scholar
  20. 20.
    Kutlu OC, Watchell M, Dissanaike S. Metastatic lymph node ratio successfully predicts prognosis in western gastric cancer patients. Surg Oncol. 2015;24:84–8.CrossRefGoogle Scholar
  21. 21.
    Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population- based study. Ann Surg Oncol. 2005;12:981–7.CrossRefGoogle Scholar
  22. 22.
    Zeng WJ, Hu WQ, Wang LW, Yan SG, Li JD, Zhao HL. Lymph node ratio is a better prognosticator than lymph node status for gastric cancer: a retrospective study of 138 cases. Oncol Lett. 2013;6:1693–700.CrossRefGoogle Scholar
  23. 23.
    Zhang BY, Yuan J, Cui ZS, Li ZW, Li XH, Lu YY. Evaluation of the prognostic value of the metastatic lymph node ratio for gastric cancer. Am J Surg. 2014;207:555–60.CrossRefGoogle Scholar
  24. 24.
    Nelen SD, van Steenbergen LN, Dassen AE, van der Wurff AA, Lemmens VE, Bosscha K. The lymph node ratio as a prognostic factor for gastric cancer. Acta Oncol. 2013;52:1751–9.CrossRefGoogle Scholar
  25. 25.
    Lee EW, Lee WY, Koo HS. Prognostic factors for node-negative advanced gastric cancer after curative gastrectomy. J Gastric Cancer. 2016;16:161–6.CrossRefGoogle Scholar
  26. 26.
    Zhao D, Xu H, Li K, Sun Z. Prognostic factors for patients after curative resection for proximal gastric cancer. J Huazhong Univ Sci Technol Med Sci. 2010;30:530–5.CrossRefGoogle Scholar
  27. 27.
    Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.CrossRefGoogle Scholar
  28. 28.
    Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III–IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84(5):e585–92.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Department of Surgical OncologyThe First Affiliated Hospital of Bengbu Medical CollegeBengbuChina

Personalised recommendations